Zavante Therapeutics has initiated the ZTI-01 Efficacy and Safety (ZEUS) study for the company’s ZTI-01, a fosfomycin for injection and an antibiotic designed to treat hospitalised patients with complicated urinary tract infections (cUTI), including acute pyelonephritis (AP).

The currently under development ZTI-01 is a broad spectrum IV antibiotic designed to treat serious infections, including those caused by multidrug-resistant (MDR) pathogens.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Zavante Therapeutics expects to complete the ZEUS study in the second half of next year.

The company noted that ZEUS is a multi-national, randomised, active-controlled, double-blind study that will provide data to support the use of ZTI-01 to address the unmet medical need of treating cUTI, including patients with MDR infections.

"The closing of our Series A financing has provided us with financial resources that we believe will be sufficient to initiate and complete the ZEUS study."

It is expected that around 110 clinical sites will participate in the study to enrol 460 hospitalised patients with cUTI, including AP.

See Also:

Titled ‘Multi-center, randomized, double-blind, comparative study to evaluate the safety and efficacy of ZTI-01 vs piperacillin/tazobactam in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults’, the study is claimed to be the single study intended to support an NDA for ZTI-01 in the US.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Zavante Therapeutics founder, president and CEO Ted Schroeder said: "The closing of our Series A financing has provided us with financial resources that we believe will be sufficient to initiate and complete the ZEUS study, with a goal of filing a New Drug Application, or NDA, for ZTI-01 with the US Food and Drug Administration (FDA) late in the second half of 2017."

The company stated that ZTI-01 has demonstrated a broad spectrum of bactericidal Gram-negative and Gram-positive activity, including activity against most contemporary MDR bacterial strains, which current antibiotic therapeutic choices are severely limited for.

In 2014, the FDA initially granted Qualified Infectious Disease Product (QIDP) designation for ZTI-01 for the indication of cUTI and last year, the FDA expanded the QIDP designations for ZTI-01 to include complicated intra-abdominal infections (cIAI), hospital-acquired bacterial pneumonia (HABP)/ventilator-associated bacterial pneumonia (VABP), and acute bacterial skin and skin structure infections (ABSSSI).

Besides, the FDA granted fast-track designations for all four QIDP designations, making ZTI-01 eligible for certain incentives available for the development of new antibiotics, including priority FDA review and an additional five-years of market exclusivity under the Generating Antibiotic Incentives Now (GAIN) Act.